The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, has announced a new collaboration with ...

Bora Biologics, a division of CDMO Bora Pharmaceuticals, will support DotBio, a biopharmaceutical company specializing in ...

BioMed X, an independent biomedical research institute based in Germany, has launched a new collaboration with Daiichi Sankyo ...

Designed and developed in-house since 2022, CS2009 has evolved into a tri-specific antibody with a novel molecular design and robust preclinical data, holding the potential to replace current anti ...

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company ...

German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi ...

MCLA-145 is under clinical development by Merus and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

CS2009 is positioned as a potential first-in-class or best-in-class next-generation immuno-oncology backbone. CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, with the potential to ...